Inclusion Criteria:

Patient older than 18 years.

- Patients with histologically proven colorectal cancer with resectable or potentially
resectable liver metastases.

- First line chemotherapy alone or combination with intravenous 5FU, oral 5FU
(capecitabine), oxaliplatin, irinotecan, cetuximab, panitumumab or bevacizumab
(LV5FU2, XELODA, FOLFIRI, FOLFOX, XELOX, XELIRI alone or in combination with either
cetuximab or panitumumab or bevacizumab).

- Signature of informed consent.

- Patient affiliated to French Social Security.

Exclusion Criteria:

Patients taking immunosuppressive therapy.

- Lack of measurable tumoral target.

- Patients with a contre-indication of all chemotherapy used: oxaliplatin, irinotecan,
fluorouracil, capecitabine, cetuximab, panitumumab, bevacizumab.

- Patients hospitalized without consent.

- Patients in emergency situations.

- Patients under guardianship.

- Patients deprived of their liberty by judicial or administrative procedure.

- Pregnant or nursing women, women without effective contraception.